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Abstract 
 
Aims 
To estimate healthcare services use and the direct medical costs accrued by patients with diabetes 
mellitus (DM) in the year of first severe hypoglycaemia (SH), the years before and after event 
year. 
 
Materials and Methods 
We analyzed a population-based, retrospective cohort including all DM adults managed in 
primary care setting from the Hong Kong Hospital Authority between 2006-2013. DM patients 
who had first recorded SH during the observation period were identified, and matched to control 
group of patients without SH based on the propensity score method. Direct medical costs in the 
years before, during and after the first SH were determined by summing up the costs of health 
services utilized within respective year.  
 
Results 
After matching, a total of 22,694 DM patients was identified in first recorded SH group 
(n=11,347) and non-SH control group (n=11,347). Patients with first SH on average utilized 7.85 
outpatient clinic visits, 1.89 emergency visits and 17.75 nights of hospitalization in the event 
year. Mean direct medical cost in the event year was US$11,751, more than twofold of that in the 
preceding year (US$4,846, p<0.001) and subsequent years (US$4,198-4,700, p<0.001), and 4.5 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
times of that in two years before the event (US$2,481, p<0.001). Incremental costs of SH versus 
matched control in the event year and preceding year were US$10,873 (p<0.001) and US$3,974 
(p<0.001), respectively. 
 
Conclusions 
SH is associated with excessive hospitalization admission rates and direct medical costs in the 
event year and, in particular, in the year before as compared to patients without SH.  
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Manuscript Text 
Introduction 
Hypoglycaemia is one of the commonest acute complications associated with intensification of 
glucose-lowering therapies, often experienced by treated with insulin. Given that insulin use 
accounts for one-fourth of all diabetes mellitus (DM) treatment [1], the number of insulin-related 
DM complications is expected to rise further with the growing number of DM by 2045 [2].  
Severe hypoglycaemia (SH) is defined as any hypoglycaemia episode requiring the emergency 
assistance from health service personnel, has been recorded as high as one in nine patients per 
year [3] among patients with type 1 and type 2 DM (T1DM and T2DM) treated with insulin. As 
well as this, the use of oral anti-diabetic drugs can also result in SH events [4]. Evidence from 
large prospective cohort studies showed that SH is associated with an accelerated cognitive 
decline in the elderly [5], an elevated risk of cardiovascular diseases [6-8], all-site cancer [9] and 
mortality [6, 7, 9, 10], with the need in emergency admissions and hospitalizations.  
 
On a global scale, SH imposes substantial economic burden onto national healthcare services, 
driven by an increasing need in blood glucose monitoring, emergency services, hospitalization, 
and additional visits to doctors and allied health professionals [11]. A number of cost-of-illness 
and cost-consequence studies have reported the direct medical cost incurred per severe 
hypoglycaemic episode across clinical characteristics in developed countries, including the 
United States (US) [12-14], United Kingdom (UK) [15, 16], Denmark [17], Netherlands [18], 
Germany [7], Spain [19-21], South Korea [22].  
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Whilst the mean costs of SH episode could be estimated, there is a scarcity of information, so far, 
on the costs in the preceding and subsequent years. Population cohort data could be used to 
estimate the direct medical costs in the year of episode, preceding and subsequent years. Use of 
population cohort data could also help in quantifying the disease burden at a national level, 
enabling an estimate of direct medical costs of patients and their determinants, such as the 
number of comorbid conditions and the presence of DM-related complications [23, 24]. This 
research extends our knowledge in the area of comparative effectiveness and cost-effectiveness 
analysis of glucose-lowering therapies focusing on the reduction of hypoglycaemic episodes and 
their associated economic impacts. 
 
The aim of the present study is to report the healthcare resource use and estimate direct medical 
costs in Hong Kong among patients with DM in the event year, preceding year and subsequent 
years of the first SH episode. We examined the influence of the socio-demographic factor 
(including gender and age) and the clinical characteristics (such as drug treatment regimen, 
duration of DM, type of DM, glycaemic control, mortality, presence of DM-related 
complications, and presence of comorbidities) on the direct medical costs of first SH, allowing 
for improved projections of healthcare expenditure incurred by DM patients suffering from SH. 
 
Materials and Methods 
Study design and patient sampling 
The population-based retrospective cohort data on 206,238 patients with DM, defined by the 
International Classification of Primary Care, Second edition (ICPC-2) codes T89/T90, who 
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visited at least one primary care general outpatient clinic or family medicine clinic under the 
Hong Kong Hospital Authority between August 1, 2008 and December 31, 2013, was extracted 
from Hospital Authority administrative database. From this broad cohort in primary care setting, 
adult DM patients with a recorded occurrence of SH episodes (identified by the International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes: 250.3, 
250.8, 251.0, 251.1, 251.2, 270.3, 775.0, 775.6 and 962.3 [25]) between January 1, 2006 and 
December 31, 2013 were identified. The index date was defined as the date of first ever SH event 
occurred during the mentioned period, with median index with of August 19, 2010. To reduce 
the bias of observations with index dates that are near the start or the end of the data period, 
patients with index dates before January 1, 2007 or after December 31, 2012 were excluded. The 
median index date for SH group was December 10, 2010. The median index date in full cohort 
and SH groups were roughly the same. 
 
A control group of DM patients who did not have any SH event in the observed period were 
matched one-to-one with the SH group using propensity score method. The patients were 
matched using their characteristics/covariates at index date of January 1, 2010 to ensure balanced 
follow-up durations and to allow for estimations of the healthcare resource uses and associated 
costs across the years. 
 
Estimation of annual direct medical costs 
The approach adopted for estimating the direct medical costs was similar to previous published 
studies [23, 24]. The annual direct medical costs were estimated by the frequency of the attended 
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healthcare service used under Hospital Authority in a year multiplied by the unit cost of the 
corresponding types of the healthcare services. The frequencies of attended healthcare services 
including general outpatient clinic (GOPC), specialist outpatient clinics (SOPC), allied health 
professional, accident & emergency (A&E) department and overnight hospitalization with 
respect to the types of wards admitted (general ward, intensive care unit (ICU), cardiac care unit 
(CCU) and high dependency unit (HDU)) between 2006-2013 were retrieved from the Hospital 
Authority administrative database. The unit cost of types of services were referred to the price 
list for non-Hong Kong residents, published in the 2013 Government Gazette and Hospital 
Authority Ordinance [26] and listed in Supplementary Table 1.  
 
The direct medical costs in the event year, denoted as year0, were estimated by aggregating the 
costs incurred from index date to 1 year after index date. The direct medical costs in the 
preceding year before event and two years before event (denoted as year-1 and year-2 
respectively) were the aggregate of the costs incurred from 1 year before index date to index 
date, and from 2 years before index date to 1 year before index date respectively. The direct 
medical costs in the first, second, and third subsequent year (denoted year+1, year+2 and year+3, 
respectively) of the first SH event were the aggregates of the costs incurred in the respective 
years. Patients who died in the subsequent years of SH event were not accounted for the cost 
calculations at the years after the death year. Inclusion of death patients with zero costs would 
underestimate the direct medical costs in subsequent years. 
 
Patient characteristics at index date 
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Patient characteristics at index date in SH and matched control groups included gender, age 
group, glycaemic control, duration of DM diagnosis, type of DM, presence of comorbidities, 
presence of DM-related complications, death within the year of first SH event occurrence, and 
DM drug regimen. DM-related complications and events of diseases were identified by the 
diagnosis codes of the ICD-9-CM and the ICPC-2. Lists of relevant diagnosis codes used in this 
study were provided in Supplementary Table 2. The DM drug regimen included lifestyle 
modification only, insulin use, oral antidiabetic drugs such as metformin, sulphonylurea, and 
other drug classes. 
 
Statistical analysis 
To assess the incremental effect of SH on direct medical costs, a group of control patients who 
had not ever been diagnosed with SH between August 1, 2008 and December 31, 2013 were 
matched by propensity score matching using the characteristics at index date in one-to-one basis. 
The use of propensity score matching is to summarize all patient¶V characteristics at index date to 
a single-index estimate, called propensity score. A propensity score was generated for each 
patient by fitting a logistic regression model of the presence of a recorded SH during the 
observation period by patient¶V characteristics. These characteristics included age, gender, 
duration of DM diagnosis, type of DM, Charlson Comorbidity index (CCI), treatment modality 
(insulin, metformin, sulphonylurea and other DM drug regimen), and existence of macrovascular 
and microvascular complications.  SH patients were then matched to the control patients based 
on the similar propensity score, i.e. similar characteristics [27, 28]. The caliper criterium 
improved the quality of the nearest neighbor matching by specifying a maximum tolerance of the 
propensity score distance between SH patients and control [29]. The propensity score matching 
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was performed by µSVPDWFK¶ command in one-to-one basis without replacement and a calliper 
criteria of 0.001 in STATA [30]. 
 
Descriptive statistics including mean, standard deviation (SD), 95% confidence interval (CI) 
were used to present the baseline demographics and clinical characteristics between the SH 
group and matched control group. Differences in baseline characteristics between two groups 
were tested using independent t-test for continuous variables or Chi-square test for categorical 
variables. The balance of the characteristics between two groups after matching was also 
indicated by standardized mean difference.  
 
Mean numbers of healthcare service utilization in the event year, years before and after the event 
year for each group were reported. Independent t-test was applied to test the mean number of 
healthcare service utilization between groups. Negative binomial regressions were performed to 
assess factors that associated with annual healthcare utilization at the event year of first SH.  
 
In order to compare the direct medical costs before and after the index years, similar approach 
was adopted to estimate the costs of the preceding and subsequent years. Mean annual direct 
medical costs in different subgroups were presented and compared using independent t-test for 
two groups, or one-way analysis of variance for three groups or above. The association between 
annual direct medical costs in the event year and baseline covariates were further analyzed by 
fitting generalized linear model with gamma family and identity link. 
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All statistical analyses were performed using STATA version 13.0 (StataCorp LP, College 
Station, TX, USA). All VLJQL¿FDQFH tests were two-tailed and P values < 0.05 were taken to 
indicate statistical VLJQL¿FDQFH 
 
Results 
The detailed flowchart of subject sampling and the distribution of propensity score matching 
between the SH group and control group are shown in Supplementary Figure 1 and 
Supplementary Figure 2, respectively.  
 
A total of 14,796 patients with a documented diagnosis of SH were identified. 11,347 patients 
remained in the cohort after excluding those who had events near the start or end date of the 
observation period. These patients were matched with a one-to-one ratio with the same number 
of control patients without any SH event. A total of 22,694 patients (11,347 patients in SH group 
and 11,347 in matched control group) were included in the analysis. 
 
Sample characteristics 
Baseline characteristics of patients in SH group and control group are shown in Supplementary 
Table 3. Though there were significant differences between the SH group and the control group 
for a number of characteristics, most of the standardized mean differences of the characteristics 
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were less than 0.1, implying that a balance was achieved in most covariates between the two 
groups.  
 
Healthcare service utilization 
Figure 1 depicts the frequency of healthcare services attendance for SH and matched control 
groups from year-2 to year+3.  
 
The mean GOPC visit in the SH group reached the highest in year-2 (5.36) and fell  
monotonically year by year and became the lowest in year+3 (3.58). A similar pattern was 
observed for GOPC visit in the control group. The mean GOPC visit in the control group was 
greater than the SH group in all years except in year-1 (for year-1: p=0.517; for other years: all 
p<0.001). 
 
There was an initial increase in the mean SOPC visit in the SH group from year-2 (2.31) to year0 
(3.30) and was followed by a subsequent monotonic decrease. The number of visits was the 
lowest in year+3 (2.25). 
 
On the other hand, the mean visit to the A&E for patients in the SH group increased from 0.44 in 
year-2 and reached a peak in the index/event year (year0) (1.89) with a subsequent fall back. In 
general, the mean A&E visit was greater for the SH group than the control group in all years 
(p<0.001). 
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The mean utilization of allied health professionals¶ services was relatively low, with less than 0.3 
for the SH group and less than 0.5 for the control group in all years.  
 
Similarly, the mean hospital night stays in ICU, CCU and HDU for overnight hospitalization in 
the SH group was fairly low, with less than 0.13, 0.05 and 0.006 in all years, respectively. The 
average night stay in general ward troughed in year-2 (3. 04) and peaked at event year (17.58). 
On the other hand, the average night stay in general ward stayed similar throughout with a mean 
of around 6 nights. Overall, patients in the SH group had a far higher mean hospitalized nights 
than that for patients in the control group (17.75 vs 0.29, p<0.001) in event year. 
 
As for healthcare services related to SH event, patients utilized overnight hospitalization the 
most in the event year (by staying in general ward), followed by the use of A&E services. In 
contrast, patients utilized A&E services the most from year+1 to year+3, followed by overnight 
hospitalization. In the event year, nearly all patients (98.6%) in SH group were admitted to a 
hospital, unlike those in the control group where only few (1.1%) were admitted.  
 
In summary, the healthcare service of outpatient visits and overnight hospitalization of general 
ward, in particular, were mostly utilized by all patients, whereas A&E service and allied health 
professionals¶ services were utilized the least. Supplementary Table 4a-4e illustrates the factors 
associated with each healthcare service within event year for SH patients.  
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Costs  
Figure 2 shows the annual average direct medical cost for SH patients and matched control from 
year-2 to year+3. In SH group, the mean cost of patients was the lowest in year-2, and reached 
the highest in event year, then dropped monotonically. The mean costs in year-1 and year+1 to 
year+3 were similar with a difference less than US$505. The mean cost in SH event year was 
US$11,751, which was more than twofold of year-1 and year+1 to year+3 and nearly 5 times of 
year-2. The mean cost related to SH was the greatest in event year which accounted for 42.1% of 
the cost, while the mean cost related to SH was similar in year+1 to year+3 and accounted for 
approximately 12-13% of the cost. 
 
The annual direct medical cost of SH patients was much higher compared to that of patients in 
control group with its approximately five times greater in year-1, year+1, year+2 and year+3. 
The mean total cost of patients was more than tenfold of that of control group in event year. 
Incremental cost of SH versus matched control in the event year was US$10,873 (95% CI: US$ 
10,502- US$11,244, p<0.001). 
 
Comparison of annual direct medical cost by time and covariates 
Table 1 presents the annual direct medical cost in the year of first SH event of each subgroup. 
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In our sample, males reported a significantly higher direct medical cost than females with the 
mean direct medical cost of male US$12,287 and that of female US$11,305 (p=0.006). 
 
The minimum mean direct medical cost was US$8,329 for patients aged below 55 up to 
US$13,120 for patients aged 75 or above in the subgroup analysis as by age group. The mean 
costs between age groups were significantly different to each other (p<0.001). 
 
Considering the direct medical cost by duration of DM (p<0.001), patients with DM for 1 to less 
than 5 years were recorded highest cost paid (US$14,345), and patients with DM for less than 1 
year and for 5-10 years had close direct medical cost for around US$11,000.  
 
In terms of the level of glycaemic control, patients with normal control (HbA1c<7%) were 
associated with significantly less direct medical cost (US$11,702) compared to those who had 
poor control (HbA1c7%) (US$12,578) (p=0.039). 
 
For mortality status in the event year, patients who died (US$24,700) were recorded more than 2 
times higher costs than that of patients who survived (US$9,552) (p<0.001).  
 
For type of DM, the two types of patients got very close direct medical cost with difference 
approximately US$23 (T1DM: US$11,728 vs. T2DM: US$11,751, p=0.991). 
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For the number of existing co-morbid conditions (p<0.001), patients having CCI of 1 got the 
minimum direct medical cost (US$6,350) while patients with CCI equal to or greater than 4 got 
the maximum direct medical cost (US$12,416). Patients with CCI of 2 and 3 had similar average 
direct medical cost (US$7,596 and US$7,527 respectively).  
 
The mean direct medical cost of patients having DM-related complications was US$15,218, 
approximately 50% higher than those without complications (US$10,082) (p<0.001).  
 
Patients receiving different treatment modalities had different direct medical costs. Insulin users 
got the highest cost with mean US$13,643 while patients with lifestyle modification had the 
lowest cost with mean US$10,509 (p<0.001). The cost associated with attending GOPC (US$176 
vs US$260, p<0.001) was significantly lower for patients having insulin than those with lifestyle 
modification, but was significantly higher in attending A&E service (US$271 vs US$141, 
p<0.001), allied health professional service (US$14 vs US$5, p<0.001), general ward 
(US$11,776 vs US9,321, p=0.001), ICU (US$758 vs US$199, p<0.001) and HDU (US$31 vs 
US6, p=0.021). Among the patients receiving oral anti-diabetic drug, patients prescribed with 
sulphonylurea was associated with the highest cost (US$12,063) but was insignificantly different 
to those on other drugs (US$10,015) (p=0.292).   
 
Figure 3 displays the mean annual direct medical cost of SH patients by year and covariates. 
Regarding the cost by gender, the costs of males and females were similar in all years with males 
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showing greater costs in year-1 and year0. For the cost by age group, SH patients of age greater 
than 75 years had the greatest cost in most years except year-2.  
 
Concerning the cost by duration of DM, SH patients suffering from DM for 1 - < 5 years got the 
highest cost throughout all years except year-2. For glycaemic control, patients with normal or 
poor control were observed with similar cost in all years. 
  
As to the cost by death group, SH patients who died within 1 year after year0 got higher costing 
from year-2 to year0 and had significantly greater increasing rate from year-1 to year0. In regard 
to cost by types of DM, SH patients suffering from T1DM had similar costing with those 
suffering from T2DM. With respect to the cost by CCI group, SH patients with CCI  4 got 
highest cost in most year except year-2. SH patients suffering from DM complication had higher 
costs than those with no DM complication in all years. For treatment modality, patients with 
insulin were observed with highest cost in all periods except year+2. To sum up, the cost of SH 
patients increased drastically from year-1 to year0 and dropped significantly from year0 to 
year+1 regardless of the covariate, so the shapes of the graphs and hence the trends were similar. 
Detailed results were shown in Supplementary Table 5a and Supplementary Table 5b for the 
direct medical costs of the patients in the years preceding and in the subsequent years of first SH 
by the covariates at index date, respectively. 
 
Table 2 presents the effect of baseline covariates on direct medical costs in the event year by 
fitting a generalized linear model with gamma family and identity link. Male patients costed 
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US$1,043 more than female patients (p=0.004). Patients who suffered from DM for 1 year to less 
than 5 years spent US1,697 than those patients suffered from DM for less than 1 year (p=0.038). 
For glycaemic control, patients who had poor control costed US$1,459 than those who had good 
control (p<0.001). Patients who died within the event year would increase the cost by US$14,235 
(p<0.001). For CCI, patients scored 2, 3 and 4 or above paid US$2,604 (p=0.024), US$2,985 
(p=0.009) and US$4,993 (p<0.001) more by comparing to the patients scored 1 respectively. 
Any history of DM-related complications would increase the medical cost by US$3,239 
(p<0.001), but the use of metformin would save US$1,742 (p=0.001). 
 
Discussion 
This study used population-based retrospective cohort data to describe the pattern of health 
service utilization and associated direct medical costs of DM patients in the event year, 
preceding years, and subsequent years of SH. The focus of the study is to estimate its economic 
impact and increased use of healthcare services associated with the occurrence of SH.  
 
Healthcare utilization in event year of SH was higher than those in the preceding and subsequent 
years. Inpatient hospitalization costs were main driver in medical expenditure across the years. 
Our further analysis of healthcare service utilizations found that patients with history of DM-
related complications and an increasing number of comorbidities were associated with greater 
hospitalization admission rates in the event year. Correspondingly, the increase in the direct 
medical costs were associated with poor glycaemic control [31], treatment intensification [32], 
incidence of DM-related complications [24, 33] and all-cause mortality [23]. The annual direct 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
medical costs grew by 95.3% from $2,481 in two years preceding the SH to $4,846 in year 
preceding the SH. Such excessive growth in annual direct medical costs might be an additional 
valuable information to be utilized in risk assessment models for occurrence of first SH.   
 
In contrast, healthcare services utilization in those without SH was lower, especially with a zero 
utilization of HDU and CCU in hospital stay during the study period. The major driver of total 
direct medical costs for matched controls was outpatient visits with a small proportion observed 
in emergency visits and allied health professionals in particular. Direct medical costs in the year 
of SH patients were approximately ten-fold higher than those without SH, primarily attributed to 
the additional length of hospital stays and emergency visits. 
 
The type of DM and insulin use are highly inter-dependent, and have been identified as 
important covariates for direct medical costs in the SH event year.  Although differences in cost 
per SH episode between patients with T1DM and T2DM exist across countries, our results were 
consistent with some published data. Using the Local Impact of Hypoglycaemia Tool for 
financial impact assessment, average direct medical cost of severe episodes for patients with 
T1DM was found to higher than those for patients with T2DM in a Spanish population [17, 21]. 
The results were similar to that for T2DM patients in Denmark [17], but less than that for T2DM 
patients in UK [16].   
 
Comparing those with and without metformin, the direct medical costs at the SH event year for 
those with metformin were lower than those without metformin. Based on the local treatment 
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regimen [34], a high proportion (23.3%) of patients only received lifestyle intervention. For 
those with HbA1c  they were given oral anti-diabetes drugs, for instance metformin, as a 
monotherapy, when there was inadequate glycaemic control [34] despite lifestyle intervention.  
 
In line with previous cost analyses [23, 24, 33], current analysis demonstrated that patients with 
poor glycaemic control, a history of DM-related complications and an increased number of 
comorbidities were associated with a high annual direct medical cost in SH event year. Given 
that a huge impact of SH occurrence, targeting those covariates were of importance in 
minimizing healthcare utilization and avoiding expensive direct medical cost in the event year, in 
both clinical and health economic perspectives. 
 
Limitations 
Although this study utilized a large retrospective cohort data, several limitations should be 
acknowledged. First, incidence of SH was identified by the first occurrence of SH captured by 
the retrospective database. Our study did not include records of SH occurred beyond the 
observation period, and records of SH requiring third-person assistance without transferring to 
hospital incurring subsequent emergency attendance and/or hospitalization. Moreover, SH 
recurrence, defined as having a patient with repeated SH records detected by ICD-9-CM 
diagnosis codes, could not identified in our retrospective database. Patients carried repeated SH 
records due to the follow-up SH episodes in outpatient clinics and hospitals. In addition, 
recognized risk factors including mild or moderate hypoglycaemia (causing non-specific 
symptoms such as tiredness, dizziness, and palpitation, etc.), insulin sensitivity, physical activity, 
dietary pattern, alcohol consumption, were neither coded in ICD-9-CM diagnosis coding nor 
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routinely recorded in our retrospective database. Finally, current cost analysis estimated public 
healthcare resource utilization and associated annual direct medical costs attributable to DM 
patients is from the perspective of Hospital Authority, which is known to be the largest public 
healthcare provider in Hong Kong. Outpatient visits and hospitalization utilized in private 
healthcare providers, SDWLHQWV¶ out-of-pocket costs, and indirect costs measured by productivity 
losses were not measurable from our retrospective cohort data. 
 
Conclusions 
SH is associated with excessive hospitalization admission rates and associated with direct 
medical costs predominately in the first event year and significantly in the year before, 
comparative to the matched control patients without SH. The population-based cohort data 
highlighted that the increased rates of emergency visits and hospitalizations in the year before the 
first event could potentially be regarded as the occurrence of SH.   
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Legends to Figures 
Figure 1. Mean annual healthcare resource use (and 95% confidence interval) in the preceding 
years, event year, and subsequent years of patients with first severe hypoglycaemia and matched 
controls 
 
Figure 2. Mean annual direct medical cost (US$, and 95% confidence interval) in the preceding 
years, event year, and subsequent years of patients with first severe hypoglycaemia and matched 
controls 
 
Figure 3. Mean annual direct medical cost (US$) in the preceding years, event year, and 
subsequent years of patients with first severe hypoglycaemia by patient covariates (from left to 
right, up to down): 1. Gender; 2. Age group; 3. Duration of diabetes; 4. Glycaemic control; 5. 
Death within first year of severe hypoglycaemia; 6. Types of diabetes; 7. Charlson comorbidity 
index; 8. History of diabetes-related complication; and 9. Treatment modality 
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Tables 
Table 1. Direct medical costs of the patients in the year of first severe hypoglycaemia by the covariates at index date 
  
N Mean (US$) SD 95% CI P-value 
Overall 11347 11751 18997 (11,401.71, 12,100.87)  
     
 
Gender 
 
   
0.006* 
Male 5157 12287 19419 (11,757.16, 12,817.42)  
Female 6190 11305 18628 (10,840.59, 11,768.90)  
     
 
Age 
 
   
<0.001* 
< 55 years 1192 8329 18554 (7,275.14, 9,383.82)  
55 - < 65 years 1527 9906 23133 (8,744.90, 11,067.30)  
65 - < 75 years 2628 11250 19348 (10,510.11, 11,990.27)  
\HDUV 6000 13120 17578 (12,675.30, 13,565.05)  
     
 
Duration of diabetes 
 
   
<0.001* 
< 1 years 1731 11512 20299 (10,554.74, 12,468.58)  
1 - < 5 years 3437 14345 21101 (13,639.18, 15,050.56)  
5 - < 10 years 2539 10951 19018 (10,210.59, 11,690.77)  
\HDUV 3640 9975 15707 (9,464.34, 10,485.19)  
     
 
Glycaemic control     0.039* 
Normal (HbA1c<7%) 4054 11702 17094 (11,175.66, 12,228.36)  
Poor +E$F 4000 12578 20807 (11,932.90, 13,222.88)  
      
Dead within the event year 
 
   
<0.001* 
Yes 1640 24770 23738 (23,620.56, 25,920.04)  
No 9707 9552 17124 (9,211.03, 9,892.43)  
     
 
Type of Diabetes 
 
   
0.991 
Insulin dependent (Type 1 diabetes) 92 11728 15543 (8,509.57, 14,947.41)  
Non-insulin dependent (Type 2 diabetes) 11255 11751 19024 (11,399.99, 12,102.97)  
     
 
Charlson Comorbidity Index 
 
   
<0.001* 
1 133 6350 17881 (3,282.85, 9,416.88)  
2 414 7596 20538 (5,611.41, 9,579.70)  
3 969 7527 17988 (6,392.78, 8,660.76)  
4 or above 9831 12416 18957 (12,040.99, 12,790.54)  
     
 
History of diabetes-related complications 
 
   
<0.001* 
Yes 3688 15218 21541 (14,522.25, 15,913.16)  
No 7659 10082 17399 (9,692.41, 10,471.85)  
     
 
Treatment modality 
 
   
<0.001*Á 
Lifestyle modification 2646 10509 17543 (9,840.19, 11,177.65)  
Insulin 638 13643 20513 (12,048.37, 15,237.84)  
Oral anti-diabetic drug 8460 11934 19136 (11,526.50, 12,342.15)  
Metformin 6248 11046 18592 (10,584.45, 11,506.64) 0.006*§ 
Sulphonylurea 7263 12063 19338 (11,618.68, 12,508.31)  
Others 100 10015 14993 (7,040.45, 12,990.45)  
HbA1c = Hemoglobin A1c; SD = Standard Deviation; CI = Confidence Interval;  
 
Notes: 
*Significant difference at 0.05 level by independent t-test or one-way analysis of variance, as appropriate. 
Other anti-diabetic drugs included DPP4, TZD, GLP1, Meglitinide and Alpha-glucosidase inhibitors. 
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ÁStatistical test on the equality of direct medical costs across three treatment modalities: "Lifestyle modification", 
"Insulin" and "Oral anti-diabetic drug". 
§ Statistical test on the equality of direct medical costs across three oral anti-diabetic drugs: "Metformin", 
"Sulphonylurea" and "Other anti-diabetic drug". 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
Table 2. Effect of baseline covariates on annual direct medical cost for patients with severe hypoglycaemia event 
within index year (Generalized linear model with gamma family and identity link function) 
Covariate Coefficient 95% CI P-value 
Constant 3,208.58 (-916.79, 7,333.94) 0.127 
$JHLQ\HDUV³´ as reference) 
 
  
55 - < 65 -679.57 (-2,333.97, 974.82) 0.421 
65 - < 75 -670.91 (-2,507.42, 1,165.60) 0.474 
 115.81 (-1,676.82, 1,908.45) 0.899 
Male (vs Female) 1,042.59 (324.00, 1,761.19) 0.004* 
Duration of GLDEHWHVLQ\HDUV³´DVUHIHUHQFH 
 
  
1 - < 5 1,696.73 (92.60, 3,300.86) 0.038* 
5 - < 10 173.47 (-1,350.58, 1,697.52) 0.823 
 -274.97 (-1,794.82, 1,244.88) 0.723 
*O\FDHPLFFRQWURO³1RUPDO+E$F´DVUHIHUHQFH 
 
 3RRU+E$F 1,458.70 (760.93, 2,156.48) <0.001* 
Dead within 1 year after diagnosis of hypoglycaemia 14,235.28 (12,022.25, 16,448.31) <0.001* 
Type 2 diabetes (vs Type 1 diabetes) 820.04 (-2,695.18, 4,335.27) 0.648 
&KDUOVRQ&RPRUELGLW\,QGH[³´DVUHIHUHQFH 
 
  
2 2,603.91 (342.75, 4,865.06) 0.024* 
3 2,985.00 (747.12, 5,222.88) 0.009* 
4 or above 4,993.42 (2,640.51, 7,346.32) <0.001* 
History of any diabetes-related complications 3,238.81 (2,330.12, 4,147.50) <0.001* 
Treatment modality 
 
  
Lifestyle modification -1,483.63 (-3,464.84, 497.59) 0.142 
Use of Insulin -327.44 (-1,845.06, 1,190.19) 0.672 
Use of Oral anti-diabetic drug 
   
Use of Metformin -1,742.26 (-2,735.89, -748.63) 0.001* 
Use of Sulphonylurea -348.09 (-1,360.81, 664.63) 0.501 
Use of Other anti-diabetic drug -1,598.10 (-3,899.31, 703.12) 0.173 
HbA1c = Hemoglobin A1c; CI = Confidence Interval; 
 
Notes: 
* Statistically significant with p-value <0.05. 
Other anti-diabetic drugs included DPP4, TZD, GLP1, Meglitinide and Alpha-glucosidase inhibitors. 
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Figure 1. Mean annual healthcare resource use (and 95% confidence interval) in the preceding years, event year, and subsequent years of patients with first 
severe hypoglycaemia and matched controls 
 
 
GOPC = general outpatient clinic; SOPC = specialist outpatient clinic; A&E = accident & emergency department; ICU = intensive care unit; CCU = cardiac 
care unit; HDU = high dependency unit 
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Figure 2. Mean annual direct medical cost (US$, and 95% confidence interval) in the preceding years, event 
year, and subsequent years of patients with first severe hypoglycaemia and matched controls 
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Figure 3. Mean annual direct medical cost (US$) in the preceding years, event year, and subsequent years of 
patients with first severe hypoglycaemia by patient covariates (from left to right, up to down): 1. Gender; 2. 
Age group; 3. Duration of diabetes; 4. Glycaemic control; 5. Death within first year of severe 
hypoglycaemia; 6. Types of diabetes; 7. Charlson comorbidity index; 8. History of diabetes-related 
complication; and 9. Treatment modality 
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